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Abstract
Background: Many ST-segment elevation myocardial infarction (STEMI) patients have
multivessel disease. There is still controversy in treatment strategy in STEMI patients with
multivessel disease. We compared clinical outcomes of multivessel revascularization with in-
farct-related artery (IRA) revascularization in STEMI patients.
Methods: The 1,644 STEMI patients with multivessel disease (1,106 in IRA group, 538 in
multivessel group) who were received primary percutaneous coronary intervention (PCI) were
analyzed from a nationwide Korea Acute Myocardial Infarction Registry. Primary endpoint
was 12-month major adverse cardiac events (MACE, defined as death, myocardial infarction,
and repeated revascularization). Secondary endpoints were 1-month MACE and each compo-
nent, stent thrombosis during 12 month follow-up, and each components of the 12-month
MACE.
Results: There were more patients with unfavorable baseline conditions in IRA group.
12-month MACE occurred in 165 (14.9%) patients in IRA group, 81 (15.1%) patients in
multivessel group (p = 0.953). There were no statistical significance in the rate of 1-month
MACE, each components of 1-month MACE, and stent thrombosis during 12 month follow-up.
Each components of 12-month MACE were occurred similarly in both groups except for target
lesion revascularization (2.4% in IRA group vs 5.9% in multivessel group, p < 0.0001). After
adjusting for confounding factors, multivessel revascularization was not associated with re-
duced 12-month MACE (OR 1.096, 95% CI 0.676–1.775, p = 0.711).
Conclusions: There were no significant differences in clinical outcomes between both groups
except for high risk of target lesion revascularization in multivessel revascularization group.
(Cardiol J 2012; 19, 3: 256–266)
Key words: myocardial infarction, coronary artery disease, percutaneous
coronary intervention
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Introduction
About 50% of acute ST-segment elevation
myocardial infarction (STEMI) patients have mul-
tivessel disease [1, 2]. STEMI patients with multi-
vessel disease are at higher risk of heart failure and
cardiogenic shock [1] and associated with two time’s
higher mortality during hospitalization and long-
-term follow-up [3, 4]. These patients show higher
incidence of acute coronary syndrome and revas-
cularization after initial intervention [5]. Recent
guidelines recommend that PCI should not be per-
formed in a non-infarct artery at the time of prima-
ry percutaneous coronary intervention (PCI) in pa-
tients without hemodynamic compromise [6].
These guidelines are based on experts’ opinions,
not on randomized controlled trials, which consid-
er safety problems such as complications related to
repeated intervention, low technical success rate,
high incidence of coronary restenosis, and renal
insufficiency following the use of contrast agents [7–
–9]. Nowadays, thanks to the technical improve-
ments in the coronary intervention field, the intro-
duction of noble drug-eluting stents, and the use of
newer anti-platelet agents, active discussions re-
garding the safety of multivessel revascularization
have been undertaken. However, in spite of the
improvement of technology and procedural tech-
niques, experts still prefers infarct-related artery
(IRA) revascularization over multivessel revasculari-
zation. Because many studies consistently showed
PCI of a non-infarct artery at the time of primary PCI
in stable patients is associated with worse clinical
outcomes [10–13]. There are still controversies, so
we are still hesitating in deciding the extent of re-
vascularization in acute STEMI setting.
Therefore, we compared the safety and effica-
cy of multivessel revascularization and IRA revas-
cularization in the setting of primary PCI in Kore-
an patients.
Methods
Study populations
From November 2005 to December 2007,
a total of 1,644 patients from the Korea Acute Myo-
cardial Infarction Registry (KAMIR) were enrolled
in the present study. KAMIR is a prospective na-
tional multicenter observational registry carried out
in about 50 tertiary hospitals in charge of primary
PCI reflecting current practice of management, risk
factors, and clinical outcomes in Korean patients
with AMI. Included patients in our study were all
diagnosed with STEMI as final diagnosis and they
had multivessel coronary disease; coronary lesions
of ≥ 50% stenosis in ≥ 2 epicardial coronary arte-
ries, and they received primary PCI. All these pa-
tients had 12 month clinical follow up. A total of
1,644 patients were divided into two groups: IRA
revascularization group (IRA group, n = 1,106,
67.3%) and multivessel revascularization group
(multivessel group, n = 538, 32.7%) (Fig. 1). Mean
age was 63.1 ± 11.8 and 73.8% were male. Mean
follow up duration was 376.4 ± 62.1 days.
The study was approved by the local bioethi-
cal committee and all patients gave their informed
consent.
Definitions and coronary angiography
The diagnosis of AMI was based on clinical
presentations, increased cardiac biomarkers (cre-
atine kinase [CK]-MB, troponin-I or troponin-T),
and 12-lead electrocardiographic findings. Among
these patients, the diagnosis of STEMI was made
Dec. 2005 to Dec. 2007
KAMIR, n = 15,156
NSTEMI 5,199
UAP 237
Others 317
No data 1,354
No PCI 843
No data 23
No primary PCI 1,448
Single vessel disease 2,466
No data 105
Follow up loss 644
No data 633
No data for culprit lesion 46
STEMI, n = 8,050
(58.3%)
PCI, n = 7,184
(89.5%)
Primary PCI,
n = 5,736 (79.8%)
Multivessel disease,
n = 2,965 (52.7%)
Follow up at 12 months,
n = 1,688 (72.4%)
Total enrolled patient,
n = 1,644
IRA revascularization group,
n = 1,106 (67.3%)
Multivessel revascularization
group, n = 538 (32.7%)
Figure 1. Study algorithm.
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when their electrocardiogram shows ST-segment
elevation of at least 1 mm in two or more contigu-
ous limb leads or 2 mm in precordial leads.
The primary PCI was defined when it is per-
formed in patients within 12 h of onset of STEMI. The
culprit artery was determined with ECG, echocardio-
graphy and angiographic findings by each operator.
The definition of IRA revascularization is re-
vascularization of only one culprit lesion in multi-
vessel coronary disease during the index hospita-
lization. The definition of multievssel revasculariza-
tion is revascularization for more than 2 coronary
vessels including culprit artery during the index
hospitalization periods. Total revascularization is
defined as revascularization of whole diseased ves-
sel during the index hospitalization. Left main le-
sion was more than 50% of diameter stenosis and
left main complex lesion was left main lesion plus
one or more epicardial coronary artery disease.
A successful PCI was documented by self-re-
porting of operator in each centers and traditionally
accepted when defined to achieve angiographic suc-
cess without associated in-hospital major clinical
outcomes such as death, MI, cerebrovascular event
and emergency coronary artery bypass grafting
(CABG). Angiographic success was defined as the
achievement of residual stenosis less than 50% and
at least TIMI flow grade II after the treatment of IRA.
All patients received loading dose of 100 to
300 mg aspirin and 300 to 900 mg clopidogrel before
the PCI. A 50 to 70 U/kg of unfractionated heparin
was loaded before or during PCI and additional
heparin was administered to patients to maintain
activated clotting time at 250 to 300 s. After the pro-
cedure, 100 mg of aspirin and 75 mg of clopidogrel
were prescribed daily. Glycoprotein (GP) IIb/IIIa
inhibitor and thrombosuction were used to patients
by the discretion of the operator.
Clinical endpoints
Baseline clinical and angiographic characteris-
tics, procedural characteristics, laboratory findings,
and medicational data were analyzed. Also, in-hos-
pital complications including in-hospital mortality
were analyzed. Primary clinical endpoint is cumu-
lative major adverse cardiac event (MACE) during
the 12-month follow up. MACE includes all cause
death, myocardial infarction, and repeated revascu-
larization; repeated PCI (re-PCI) and CABG. Re-
PCI includes target lesion revascularization (TLR),
target vessel revascularization (TVR), and non-tar-
get vessel revascularization (non-TVR).
Secondary endpoints are defined as MACE and
each component during 1-month follow up, stent
thrombosis during 12-month follow up, and each com-
ponents of MACE during the 12-month follow up.
TLR was defined as re-PCI for restenosis or
other complications of lesion which was treated
segment from 5mm proximal and 5 mm distal to the
stent. TVR was defined as repeated PCI for any
segment of entire coronary artery proximal and dis-
tal to target lesion except for target lesion.
Statistical analysis
We analyzed data with SPSS ver. 18.0 (Statis-
tical Package for the Social Sciences, SPSS Inc.,
USA). Continuous variables were demonstrated as
mean ± standard deviation or median value. They
were analyzed with student t-test. Nominal varia-
bles were demonstrated as percentage and ana-
lyzed with the c2 test or Fisher’s exact test when
appropriate. To compare cumulative 12 month
MACE and event rates between both groups, Cox
regression analysis was used. All variables which
showed significances in univariate analysis (p < 0.1)
for endpoints and the other variables that have been
reported to be associated with prognosis of patients
with AMI were included in adjusting Cox regres-
sion models. Included variables were age, gender,
previous PCI history, previous hypertension histo-
ry, initial left ventricular ejection fraction (LVEF)
less than 40%, 3 vessel disease, Killip class III/IV,
pre-TIMI flow grade 0, post-TIMI flow grade 3, cur-
rent smoker, stent diameter implanted in the culprit
vessel, implanted stent number per patient, success-
ful PCI, defibrillation or cardioversion during the
procedure, maximal CK-MB level, initial LDL level,
prescription of cilostazol, clopidogrel, beta-blocker,
statin, or ARB during the hospitalization, prescription
of cilostazol at discharge, and whether carry out fol-
low up coronary angiography or not. All analyses were
2-tailed and all variables were considered significant
if p-value was less than 0.05.
Results
Baseline characteristics
Of the total 1,644 patients, 1,106 (67.3%) pa-
tients were IRA revascularization group and 538
(32.7%) patients were multivessel revascularization
group. Mean age was 63.6 years in the IRA group
and 62.1 years in multivessel group (p = 0.014).
There was no significant difference in the rate of
male between the two groups (72.3% vs 76.8%,
p = 0.055). The patients in IRA group were older,
more hypertensive, had more previous PCI histo-
ry, and more previous aminosalicylic acid medica-
tion history. Also, at the initial laboratory findings,
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the patients in the IRA group had higher peak CK-
-MB and lower LDL cholesterol level. Almost ev-
ery patients in the study were administered aspi-
rin and clopidogrel. The prescription rates of beta-
-blocker, angiotensin receptor blocker (ARB), statin,
cilostazol, clopidogrel in hospitalization were high-
er in the multivessel group (Table 1). However, at
the time of discharge, the prescription rates became
similar except for cilostazol, which was more high-
ly prescribed in multivessel group. Mean follow
up duration was similar in both groups (374.9 vs
379.5 days, p = 0.168). Patients who had initial
LVEF less than 40% were higher in the IRA group
(72.5% vs 27.6%, p = 0.048).
Angiographic and procedural characteristics
The angiographic and procedural characteris-
tics were described in the Table 2. In the IRA group,
the incidence of 3 vessel disease was lower than
multivessel disease (39.0% vs 44.4%, p = 0.035).
There were more pre TIMI flow 0 patients and less
post TIMI 3 patients in the IRA group and they were
less treated with stenting and GP IIb/IIIa inhibitors.
The number of stents which were implanted in the
IRA group was small and the stent diameter was
also small in that group. There were no significant
differences in IRA, significance of lesion, length of
stents implanted in target lesion, and procedural
success rate. Almost every patients were implanted
with drug-eluting stent (91.3% vs 89.0%, p = 0.160).
Incidence of follow up angiography at 6–9 months
was significantly higher in multivessel group (43.8%
vs 52.8%, p < 0.0001).
Clinical endpoints
There was no significant difference in primary
endpoint, the rate of cumulative MACE during the
12-month follow up [165 patients (14.9%) vs 81 pa-
tients (15.1%), p = 0.953] (Table 3). As one of our
secondary endpoints, rates of each component of
12-month cumulative MACE were also similar be-
tween both groups, except for TLR, which showed
higher rate in multivessel group (5.9% vs 2.4%,
p < 0.0001). The rate of stent thrombosis was simi-
lar between both groups (0.9% vs 2.6%, p = 0.097).
The incidence of in-hospital mortality was sim-
ilar in both groups (0.5% vs 0.4%, p = NS). There
were no significant differences in rate of cardiogenic
shock needing intra-aortic balloon pump insertion,
cerebrovascular accident, new onset heart failure,
major bleeding, or acute renal insufficiency between
the two groups. But the rate of defibrillation/car-
dioversion due to ventricular tachycardia or fibril-
lation was lower in the multivessel group (4.5% vs
2.4%, p = 0.037) (Table 4).
The rate of 1 month MACE was also similar
between two groups (35 [3.2%] vs 14 [2.6%] pa-
tients, p = 0.529) and the same for each components
(Table 5).
Because there were significant differences in
baseline characteristics, clinical status, and compli-
cations that occurred during hospitalization between
both groups. We adjusted confounding factors such
as age, gender, hypertension history, previous PCI
history, previous medication history, pre- and post-
-TIMI flow grade, initial LVEF less than 40%, coro-
nary disease extent, stent diameter, stenting, peak
CK-MB and initial LDL cholesterol level, medication
during hospitalization and at the time of discharge.
Adjusted odds ratio of 12-month MACE calculated
from multivariate logistic regression analysis was
1.085 (p = 0.757, 95% CI 0.647–1.817). There were
no significant differences in odds ratio for death, MI,
re-PCI, TLR, and non-TVR during 12 month follow
up. The odds ratio of multivessel revascularization
for TVR was 0.249 (95% CI 0.074–0.834, p = 0.024)
with statistical significance. Cox regression analysis
showed similar results (Table 6, Figs. 2, 3).
Discussion
The main result of our study was that multi-
vessel revascularization showed similar clinical
outcomes compared with IRA revascularization
during the 12-month follow up. Although this study
was an observational registry, it is worthy in that it
analyzed a relatively large number of patients with-
out strict exclusion criteria and reflecting recent
treatment tendency. Results in this study are com-
parable with previous studies, so we think that our
study qualifies as important evidence-based data.
Primary PCI in acute STEMI patients is a pri-
mary target of treatment, as it has reduced the rate
of death and MACE. Of these acute STEMI patients,
many have multivessel disease, for which recent
treatment guidelines recommend IRA revascular-
ization, except for the case of hemodynamic insta-
bility, which can be managed with multivessel re-
vascularization [6]. The evidence for the recent
guideline is level of C considering experts’ opinions
that IRA revascularization is better than multivessel
revascularization in cost-effectiveness and safety.
Because short- and long-term mortality of
acute STEMI patients with multivessel disease are
higher than those with single-vessel disease [1, 3, 4],
it seems that non-IRA revascularization at the
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Table 1. Baseline clinical characteristics.
Total IRA revascularization Multivessel revascularization P
(n = 1,644) (n = 1,106, 67.3%)   (n = 538, 32.7%)
Age (years) 63.1±11.8 63.6±12.0 62.1±11.1 0.014
Male 1213 (73.8%) 800 (72.3%) 413 (76.8%) 0.055
Current smoker 747 (45.7%) 484 (44.0%) 263 (49.1%) 0.055
DM 484 (29.8%) 323 (29.6%) 161 (30.3%) 0.769
Hypertension 860 (52.8%) 604 (55.2%) 256 (47.9%) 0.005
Dyslipidemia 143 (9.9%) 103 (10.8%) 40 (8.1%) 0.106
Prev. MI 42 (2.6%) 29 (2.6%) 13 (2.4%) 0.804
Prev. PCI 76 (4.6%) 59 (5.3%) 17 (3.2%) 0.049
Prev. CABG 8 (0.5%) 7 (0.6%0 1 (0.2%) 0.286
Prev. CVA 99 (6.0%) 73 (6.6%) 26 (4.8%) 0.157
Family history of IHD 135 (8.9%) 81 (8.1%) 54 (10.6%) 0.103
Ant. wall in ECG 767 (46.7%) 505 (45.7%) 262 (48.7%) 0.247
Past medication-ASA 168 (10.2%) 133 (12.0%) 35 (6.5%) 0.001
Past medication-statin 81 (4.9%) 60 (5.4%) 21 (3.9%) 0.181
Killip class III/IV: 180 (11.2%) 126 (11.8%) 54 (10.1%) 0.323
I 1193 (74.3%) 782 (72.9%) 411 (77.0%) 0.081
II 232 (14.4%) 163 (15.2%) 69 (12.9%)
III 91 (5.7%) 60 (5.6%) 31 (5.8%)
IV 90 (5.6%) 67 (6.3%) 23 (4.3%)
SBP < 90 mm Hg 112 (6.9%) 82 (7.5%) 30 (5.6%) 0.165
SBP [mm Hg] 126.3 ± 29.1 125.9 ± 29.4 127.3 ± 28.4 0.349
DBP [mm Hg] 78.3 ± 25.2 78.2 ± 28.6 78.5 ± 16.4 0.786
HR [bpm] 75.3 ± 19.5 75.4 ± 19.9 75.1 ± 18.5 0.815
Cr [mg/dL] 1.1 ± 0.9 1.1 ± 0.6 1.1 ± 1.2 0.888
Peak TnI [ng/mL] 63.9 ± 104.2 64.3 ± 100.7 63.1 ± 110.4 0.845
Peak CK-MB 182.7 ± 287.7 197.0 ± 321.0 153.37 ± 199.88 0.001
TC [mg/dL] 184.8 ± 44.0 183.7 ± 44.0 186.9 ± 44.1 0.171
TG [mg/dL] 128.9 ± 106.8 128.4 ± 105.6 129.8 ± 109.2 0.813
HDL-C [mg/dL] 43.7 ± 16.7 43.5 ± 19.0 44.0 ± 10.7 0.596
LDL-C [mg/dL] 118.9 ± 37.6 117.3 ± 36.5 122.1 ± 39.4 0.020
CRP [mg/dL] 0.8 (0.2–4.2) 0.5 (0.2–3.3) 0.5 (0.1–1.6) 0.538
BNP [pg/mL] 80 (17–327) 60.0 (18.0–277.3) 156.5 (26.5–327.8) 0.695
Medications:
Aspirin 1632 (99.3%) 1095 (99.0%) 537 (99.8%) 0.118
Clopidogrel 1624 (98.8%) 1088 (98.4%) 536 (99.6%) 0.029
Cilostazol 593 (36.1%) 308 (27.8%) 285 (53.0%) < 0.0001
Beta-blocker 1252 (76.2%) 812 (73.4%) 440 (81.8%) < 0.0001
ACE-I 1174 (71.4%) 773 (69.9%) 401 (74.5%) 0.051
ARB 224 (13.6%) 137 (12.4%) 76 (16.2%) 0.036
Statin 1256 (76.4%) 816 (76.8%) 440 (81.8%) < 0.0001
Discharge medication:
Aspirin 1607 (97.7%) 1081 (97.7%) 526 (97.8%) 0.969
Clopidogrel 1593 (96.9%) 1070 (94.7%) 523 (97.2%) 0.608
Cilostazol 593 (36.1%) 308 (27.8%) 285 (53.0%) < 0.0001
Beta-blocker 1235 (75.1%) 818 (74.0%) 417 (77.5%) 0.118
ACE-I 1130 (68.7%) 749 (67.7%) 381 (70.8%) 0.204
Statin 1261 (76.7%) 838 (75.8%) 423 (87.6%) 0.199
Follow up duration 374 (356–396) 370.5 (356.0–394.8) 358.5 (329.3–374.5) 0.017
IRA — infarct-related artery; DM — diabetes mellitus; MI — myocardial infarction; PCI — percutaneous coronary intervention; CABG — coronary artery
bypass graft surgery; CVA — cerebrovascular accident; IHD — ischemic heart disease; ECG — electrocardiogram; ASA — aminosalicylic acid; SBP —
systolic blood pressure; DBP — diastolic blood pressure; HR — heart rate; Cr — creatinine; TnI — troponin I; CK-MB — creatine kinase MB; TC — total
cholesterol; TG — triglyceride; HDL-C — high density lipoprotein cholesterol; LDL-C — low density lipoprotein cholesterol; CRP — C-reactive protein;
BNP — B-type natriuretic peptide; ACE-I — angiotensin converting enzyme inhibitor; ARB — angiotensin receptor blocker
261
Hye Won Lee et al., Multivessel PCI in STEMI with multivessel disease
www.cardiologyjournal.org
same time as primary PCI would maximize recov-
ery of whole ventricular function by improving
myocardial perfusion, thereby producing better clini-
cal outcomes. Actually, it is known that vulnerable
plaque distribution is generally not limited only to IRA
in acute coronary syndrome, accounting for the recur-
rence of angina pectoris, acute coronary syndrome,
and need for re-PCI of non-IRA [5, 14]. This supposi-
tion is supported by the fact that the introduction of
drug-eluting stents has reduced restenosis of lesions
and need for re-PCI [15], and by the fact that clinical
results of multivessel revascularization have been
improved with these technical development and use
of a variety of GP IIb/IIIa inhibitors [16–18].
Table 2. Angiographic and procedural characteristics.
Total IRA revascularization Multivessel revascularization P
(n = 1,644)  (n = 1,106, 67.3%)  (n = 538, 32.7%)
Disease extent:
2VD 974 (59.2%) 675 (61.0%) 299 (55.6%) 0.035
3VD 670 (40.8%) 431 (39.0%) 239 (44.4%)
Successful PCI 1583 (97.0%) 1058 (96.4%) 525 (98.1%) 0.061
Pre-TIMI 0: 903 (56.0%) 636 (58.8%) 267 (50.7%) 0.001
0 903 (56.0%) 636 (58.8%) 267 (50.3%) 0.003
1 140 (8.7%) 84 (7.8%) 56 (10.5%)
2 241 (15.0%) 160 (14.8%) 81 (15.3%)
3 328 (20.3%) 201 (18.6%) 127 (23.9%)
Post-TIMI 3: 1496 (93.2%) 986 (91.8%) 510 (95.9%) 0.002
0 17 (1.1%) 15 (1.4%) 2 (0.4%) 0.009
1 10 (0.6%) 5 (0.5%) 5 (0.9%)
2 83 (5.2%) 68 (6.3%) 15 (2.8%)
3 1496 (93.2%) 986 (91.8%) 510 (95.9%)
Culprit vessel:
LM 22 (1.3%) 10 (0.9%) 12 (2.2%) 0.384
LAD 716 (43.6%) 488 (44.2%) 228 (42.4%)
LCX 188 (11.4%) 112 (10.1%) 76 (14.1%)
RCA 717 (43.6%) 495 (44.8%) 222 (41.3%)
Type B2/C: 1277 (81.3%) 858 (82.3%) 419 (79.5%) 0.186
A 49 (3.1%) 31 (3.0%) 18 (3.4%) 0.006
B1 244 (15.5%) 154 (14.8%) 90 (17.1%)
B2 414 (26.4%) 252 (24.2%) 162 (30.7%)
C 863 (55.0%) 606 (58.1%) 257 (48.8%)
Total revascularization 396 (24.1%) 0 396 (73.6%) < 0.0001
PCI with stent: 1570 (95.9%) 1047 (95.1%) 523 (97.6%) 0.018
BMS 147 (9.5%) 90 (8.7%) 57 (11.0%) 0.160
DES 1402 (90.5%) 939 (91.3%) 463 (89.0%)
Stent number/pt. 1.7 ± 0.9 1.4 ± 0.6 2.4 ± 1.0 < 0.0001
Stent length of IRA/pt. [mm] 25.6 ± 6.4 25.8 ± 6.4 25.4 ± 6.2 0.325
Stent diameter of IRA [mm] 3.19 ± 0.42  3.17 ± 0.43  3.23 ± 0.40  0.018
GP IIb/IIIa inhibitor 187 (27.8%) 102 (22.9%) 85 (37.6%) < 0.0001
Initial LVEF < 40% 214/1535 (13.4%) 155/1021 (72.45) 59/514 (27.6%) 0.048
Follow-up coronary 763 (46.7%) 481 (43.8%) 282 (52.8%) < 0.001
angiography
Complications 248 (15.2%) 174 (15.9%) 74 (13.8%) 0.258
Days in CCU 3.4 ± 3.0 3.5 ± 3.29 3.38 ± 2.44 0.598
IRA — infarct related artery; VD — vessel disease; PCI — percutaneous coronary intervention; TIMI — thrombolysis in myocardial infarction; LM — left
main; LAD — left anterior descending artery; LCX — left circumflex artery; RCA — right coronary artery; BMS — bare metal stent; DES — drug-eluting
stent; GP IIb/IIIa inhibitor — glycoprotein IIb/IIIa inhibitor; LVEF — left ventricular ejection fraction; CCU — coronary care unit
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Table 4. In-hospital outcomes.
Total IRA revascularization Multivessel revascularization P
(n = 1,644) (n = 1,106, 67.3%)   (n = 538, 32.7%)
In-hospital mortality: 8 (0.5%) 6 (0.5%) 2 (0.4%) NS
Cardiac 8 6 2 NS
Non-cardiac 0 0 0 NS
Complications: 248 (15.2%) 174 (15.9%) 74 (13.8%) 0.258
IABP 78 (4.7%) 51 (4.6%) 27 (5.0%) 0.715
CVA 7 (0.4%) 7 (0.6%) 0 0.104
Acute renal failure 4 (0.2%) 3 (0.3%) 1 (0.2%) NS
Defib/cardioversion 63 (3.8%) 50 (4.5%) 13 (2.4%) 0.037
due to VT or VFib
Major bleeding 3 (0.2%) 2 (0.2%) 1 (0.2%) NS
New onset HF 11 (0.7%) 10 (0.9%) 1 (0.2%) 0.115
IRA — infarct related artery; IABP — intra-aortic balloon pump; CVA — cerebrovascular accident; Defib — defibrillation; VT — ventricular tachycardia;
VFib — ventricular fibrillation; HF — heart failure
Table 5. One month major adverse cardiac events.
Total IRA revascularization Multivessel revascularization P
(n = 1,644) (n = 1,106, 67.3%) (n = 538, 32.7%)
One-month MACE 49 (3.0%) 35 (3.2%) 14 (2.6%) 0.529
Death 12 (0.7%) 7 (0.6%) 5 (0.9%) 0.543
   Cardiac death 12 (0.7%) 7 (0.6%) 5 (0.9%) 0.543
   Non-cardiac death 0 0 0 0
MI 7 (0.4%) 4 (0.4%) 3 (0.6%) 0.689
Repeated PCI 26 (1.6%) 22 (2.0%) 4 (0.7%) 0.057
TLR 2 (0.1%) 1 (0.1%) 1 (0.2%) 0.548
TVR 1 (0.1%) 1 (0.1%) 0 NS
TLR/TVR 3 (0.2%) 2 (0.2%) 1 (0.2%) NS
Non-TVR 22 (1.3%) 19 (1.7%) 3 (0.6%) 0.066
CABG 2 (0.1%) 0 2 (0.4%) 0.107
MACE — major adverse cardiovascular event; MI — myocardial infarction; PCI — percutaneous coronary intervention; TLR — target lesion revasculariza-
tion; TVR — target vessel revascularization; non-TVR — non-target vessel revascularization; CABG — coronary artery bypass graft; NS — non-specific
Table 3. Twelve month cumulative major adverse cardiac events and stent thrombosis.
Total IRA revascularization Multivessel revascularization P
(n = 1,644) (n = 1,106, 67.3%)  (n = 538, 32.7%)
12-month MACE 246 (15.0%) 165 (14.9%) 81 (15.1%) 0.953
Death 34 (2.1%) 25 (2.3%) 9 (1.7%) 0.429
   Cardiac death 23 (1.4%) 15 (1.4%) 8 (1.5%) 0.836
   Non-cardiac death 11 (0.7%) 10 (0.9%) 1 (0.2%) 0.115
MI 11 (0.7%) 7 (0.6%) 4 (0.7%) 0.799
Repeated PCI 195 (11.9%) 129 (11.7%) 66 (12.3%) 0.732
TLR 59 (3.6%) 27 (2.4%) 32 (5.9%) < 0.0001
TVR 27 (1.6%) 21 (1.9%) 6 (1.1%) 0.239
Non-TVR 109 (6.6%) 81 (7.3%) 28 (5.2%) 0.103
CABG 6 (0.4%) 4 (0.4%) 2 (0.4%) 0.976
Stent thrombosis 10 (1.5%) 4 (0.9%) 6 (2.6%) 0.097
MACE — major adverse cardiovascular event; MI — myocardial infarction; PCI — percutaneous coronary intervention; TLR — target lesion revasculariza-
tion; TVR — target vessel revascularization; non-TVR — non-target vessel revascularization; CABG — coronary artery bypass graft; NS — non-specific
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On the other hand, the severity of non-target
lesion might be more exaggerated than it really is
because of vasoconstriction due to increased blood
level of catecholamine, which commonly happens
in the setting of acute myocardial infarction [19].
And it can be a more severe problem, especially
when lesion severity is measured by bare eyesight
and not by quantitative coronary angiographic me-
thods. One randomized controlled trial compared
procedures according to bare eyesight and fractional
flow reserve (FFR), and it revealed that more pro-
cedures were done and the rates of MACE were
higher in patients whose procedures were guided
by bare eyesight than by FFR [20]. Therefore, it can
also be said that IRA revascularization might be
a suitable option due to the risk of overestimation
of intermediate coronary lesions such a hypercoa-
gulable status, as in acute coronary syndrome.
Previous studies have represented a variety of
conclusions: some reported that IRA revasculariza-
tion is better [8, 21], some reported that both strat-
egies are similar in clinical outcomes [22–23], and
some concluded that multivessel revascularization
is more beneficial than IRA revascularization [24–
–26]. Even recently, two meta-analyses reported
different conclusions. A meta-analysis by Navarese
et al. [27] that included two RCTs and eight non-
randomized controlled trials not considering staged
revascularization showed results that multivessel
revascularization reduced re-PCI, but did not re-
duce death or myocardial infarction. Another meta-
analysis by Sethi et al. [28] that included two RCTs
and nine non-randomized controlled trials report-
ed that there were no significant differences in rates
of MACE or long-term mortality between the two
strategies, but it excluded all cardiogenic shock
patients.
Because our study is a multicenter observa-
tional registry with no strict inclusion and exclu-
sion criteria, selection bias might be inherent. Ac-
tually, there were more unfavorable factors in the
IRA group compared with multivessel group. There
were more patients with hypertension and previ-
ous PCI history, as well as older patients and more
women in the IRA revascularization group. Patients
in the IRA revascularization group had higher rate
of pre-TIMI 0 flow initially, and lower rate of post-
TIMI 3 flow grade. They used less GP IIb/IIIa in-
hibitors and had lower LVEF initially. This might
be presumed to be because the operators chose IRA
revascularization for patients who arrived with un-
favorable clinical and angiographic conditions to
minimize procedure time and procedure-related
complications including reperfusion arrhythmia.
However, after adjusting all of these confounding
factors, there was no statistical significance in
Table 6. Odds ratio (OR) for 12 month clinical outcomes with multivessel revascularization.
12 month clinical Unadjusted OR P Adjusted OR P
outcomes  (95% confidence interval) (95% confidence interval)
Death 0.734 (0.340–1.584) 0.431 1.198 (0.333–4.317) 0.782
MI 1.174 (0.342–4.027) 0.799 1.474 (0.400–5.433) 0.560
Re-PCI 1.057 (0.770–1.450) 0.732 1.025 (0.716–1.468) 0.892
TLR 2.253 (1.495–4.256) 0.001 1.903 (0.728–4.974) 0.189
TVR 0.582 (0.230–1.450) 0.245 0.249 (0.074–0.834) 0.024
Non-TVR 0.693 (0.445–1.079) 0.105 1.144 (0.563–2.328) 0.710
CABG 1.026 (0.187–5.620) 0.976 – –
12 month MACE 1.009 (0.756–1.346) 0.953 1.085 (0.647–1.817) 0.757
MI — myocardial infarction; PCI — percutaneous coronary intervention; TLR — target lesion revascularization; TVR — target vessel revascularization;
non-TVR — non-target vessel revascularization; CABG — coronary artery bypass graft; MACE — major adverse cardiovascular event
Figure 2. Twelve month survival free from major adverse
cardiovascular event (MACE) in multivessel and infarct-
-related artery (IRA) revascularization groups.
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12 month MACE. These results reflect that recent
technical improvement and the aid of adjuvant medi-
cal treatment augmented the benefits of multives-
sel revascularization in this study.
More recently, there were many studies com-
paring the effects of staged PCI with IRA and mul-
tivessel revascularization. An analysis from HORI-
ZONS-AMI (Harmonizing Outcomes With Revas-
cularization and Stents in Acute Myocardial
Infarction) Trial by Kornowski et al. [13] compared
one time multivessel PCI vs staged PCI and result-
ed that multivessel PCI might be associated with
hazard for mortality and stent thrombosis. Hannan
et al. [29] analyzed 3,521 STEMI patients as treat-
ment strategy of culprit vessel PCI during the in-
dex procedure, staged PCI during the index admis-
sion, and staged PCI after the index procedure but
within 60 days with propensity matching analysis.
The results showed that there were no statistical
differences in clinical outcomes between culprit
vessel PCI during the index procedure group and
staged PCI during the index admission. And patients
underwent staged multivessel revascularization
after the index procedure but within 60 days showed
significantly lower mortality rates at 12 month fol-
low up. That study supports the recent guidelines
and suggests staged PCI after the index procedure.
In addition to that, recently a meta-analysis includ-
ing Hannan’s study by Vlaar et al. [12] revealed that
multivessel revascularization at the index proce-
dure should be deferred and PCI for the significant
non-culprit lesion should be done at planned staged
procedures.
In this study, we could not classify multives-
sel revascularization at the index procedure and
staged PCI at the index hospitalization. Also, there
exists the possibility that staged PCI after the in-
dex hospitalization might be counted as non-TVR.
Figure 3. Twelve month survival free from re-percutaneous coronary intervention (PCI), target lesion revasculariza-
tion (TLR), target vessel revascularization (TVR), and non-TVR in multivessel and infarct-related artery (IRA) revascu-
larization groups.
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So, the incidence of non-TVR in the IRA group
might be over-estimated. That’s why there was no
benefit of reducing non-TVR in the multivessel
group in this study. Although multivessel revascu-
larization group includes staged PCI during the in-
dex admission in this study, on the assumption that
the effect of staged PCI during the index admission
is equal to that of IRA revascularization, our results
presents that multivessel revascularization might
be equally safe and beneficial compared with IRA
revascularization. Because in-hospital outcomes in
this study show that there are no significant differ-
ences in total complications, acute renal failure,
major bleeding, etc. On the contrary, there was
more defibrillation/cardioversion due to ventricu-
lar tachycardia or ventricular fibrillation. An analy-
sis of effect of multivessel over IRA revasculariza-
tion in NSTEMI patients by Kim et al. [30] from KA-
MIR registry, which was conducted in our country
as same procedural environment with this study
presented that the beneficial effect of multivessel
revascularization. In the acute myocardial infarction
setting including STEMI and NSTEMI, to know
what is the exact culprit artery is very challenging
thing. Sometimes suboptimal results after PCI
comes from not only complications related to pro-
cedures but also from such a confusing situations
not knowing the exact culprit artery. So we think
that with aid of functional examination of culprit
artery and technical, medicational improvements in
the procedural field, complications and limitations
of multivessel revascularization would be overwhelmed.
Regarding limitations of our study, first there
is selection bias because of the characteristics of
our study. Second, as our study was based on ob-
servational registry, technical aspects and criteria
of clinical outcomes were not standardized, especial-
ly in determining IRA. Third, we did not consider
staged revascularization due to limitation of data.
Conclusions
Summarizing the results of our study, there
were no significant differences between IRA revas-
cularization and multivessel revascularization in the
rates of 12-month MACE, and each components
except for high rate of TVR in the multivessel
group. Also, there were no statistical differences in
in-hospital mortality and composite of complica-
tions, 1-month MACE and each component. Our
conclusion is that our results support current guide-
lines that recommend IRA revascularization in he-
modynamic stable STEMI patients in the setting of
primary PCI. In addition to that, we cautiously sug-
gest that multivessel revascularization might be
equally safe and beneficial compared with IRA re-
vascularization especially done by experienced in-
terventional cardiologist and in the case of multi-
ple culprit lesion is suspected.
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